Kensey Nash Evaluating Aegis Vortex Atherectomy System In Pilot Study
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash's recently initiated pilot study for its Aegis Vortex System (AVS) for treating occluded saphenous vein grafts is designed to support FDA approval for an estimated 300-patient pivotal trial.
You may also be interested in...
Kensey Nash
Secondary offering of 3.2 mil. shares of common stock at $9.50 each includes 2.7 mil. shares offered by the company and 500,000 offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds also will be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group was lead manager of the offering; PaineWebber and UBS Warburg were co-managers
Kensey Nash
Secondary offering of 3.2 mil. shares of common stock at $9.50 each includes 2.7 mil. shares offered by the company and 500,000 offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds also will be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group was lead manager of the offering; PaineWebber and UBS Warburg were co-managers
Kensey Nash
Proposed secondary offering of 3.2 mil. shares of common stock includes 2.5 mil. shares to be offered by the company and 700,000 shares to be offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds will also be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group is lead manager of the offering; PaineWebber and Warburg Dillon Read will act as co-managers